Launch
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer
What's New: Drugs RSS Feed · By FDA ·
The Brief
- On December 18, 2024, the FDA approved ensartinib (brand name Ensacove, from Xcovery Holdings, Inc.).
- The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have not previously received an ALK inhibitor.
- The source is an FDA approval notice, republished in a drugs RSS feed dated 2026-11-07.
Why it matters
It adds an oral targeted treatment option for a defined subgroup of lung cancer patients, and it is relevant to oncology researchers and clinicians tracking ALK-inhibitor therapies.
Who’s affected
- Adults with ALK-positive locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor
- #oncology
- #lung cancer
- #alk inhibitor
- #fda approval
- #targeted therapy
On December 18, 2024, the Food and Drug Administration approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an…
Timeline
FDA approves ensartinib (Ensacove) for ALK-positive NSCLC
What's New: Drugs RSS Feed
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer